EXOMIND BTL 699 2 and EMSELLA HPM 6000UF Trials Assess Postpartum

Meta description: A ClinicalTrials.gov trial evaluates two noninvasive devices for postpartum depressive symptoms and urinary incontinence, using active and sham arms, with sponsor BTL Industries Ltd. Recruitment is listed as ongoing as of February 19 2026.

The regulatory community and medical device developers should review the study design and current status to support oversight, monitoring, and planning for future work in this indication set.

What changed in the postpartum device trial landscape?

The ClinicalTrials.gov record identifies two therapeutic devices from BTL Industries used within a single study that targets postpartum women with depressive symptoms and urinary incontinence. The entry documents active treatment arms for both devices as well as sham treatment arms, indicating a four arm design intended to compare active therapy against sham control.

Device EXOMIND BTL 699 2 and device EMSELLA HPM 6000UF are each listed in active treatment and sham treatment formats. The sponsor listed for the trial is BTL Industries Ltd. The study status is recruiting, which implies ongoing evaluation of safety signals and potential efficacy indicators in the defined population.

These details are drawn directly from the ClinicalTrials.gov record linked to the identifier NCT07413692. The source confirms the conditions under study as depressive symptoms and urinary incontinence in postpartum related cohorts. This information is relevant for regulatory teams monitoring device based interventions in postpartum care and for manufacturers evaluating similar trial designs.

For readers seeking more context, see the ClinicalTrials.gov entry at ClinicalTrials.gov NCT07413692.

How is the study designed and described in regulatory terms?

The record outlines a four arm design with two active therapy arms and two sham arms. The active interventions involve EXOMIND BTL 699 2 and EMSELLA HPM 6000UF. The paired sham arms provide controls for each device, enabling comparative assessment of safety signals without therapeutic effect than the sham practice allows.

The sponsor is listed as BTL Industries Ltd. The entry notes that the study is currently recruiting, a status that regulatory teams should track for changes in enrollment, safety reporting obligations, and potential amendments to the protocol. The identifier NCT07413692 anchors the record in ClinicalTrials.gov, a primary registry used for regulatory transparency and post market surveillance planning.

Interventions and controls

Active treatment arms are EXOMIND BTL 699 2 and EMSELLA HPM 6000UF. Sham treatment arms correspond to the same devices without therapeutic effect. The design aims to provide a basis for regulatory assessment of technology driven approaches for depressive symptoms and urinary incontinence in a postpartum population.

Who is the target population and what does that imply for regulation?

The study targets postpartum and early post childbirth women presenting depressive symptoms and urinary incontinence. This specific population is important for regulators because it informs device labeling, risk management, and monitoring plans in a population that may have unique physiological and psychosocial considerations after birth.

Because the intervention involves noninvasive devices, the regulatory focus includes assessment of device safety in population specific contexts, compatibility with concurrent postnatal care practices, and clarity around the intended use as described by the sponsor. The inclusion of both active and sham arms supports differentiating true device related effects from placebo responses while maintaining trial integrity for regulatory evaluation.

Sponsor and status what to watch for

The sponsor listed for this study is BTL Industries Ltd. The record indicates recruitment ongoing as of the publication time. Regulatory teams should monitor updates to recruitment status, any protocol amendments, and adverse event reporting requirements that accompany the launch and progression of a four arm trial with two devices. The presence of sham arms necessitates careful consideration of blinding and data integrity in relation to regulatory expectations for device controlled studies.

What is the regulatory context for this trial?

The entry aligns with standard regulatory practice by documenting device specific identifiers, intended indications that include depressive symptoms and urinary incontinence after childbirth, and a controlled trial design with active and sham arms. The information is sourced from ClinicalTrials.gov and reflects a transparency driven approach common in medical device regulation. Observers should note the exact device names, sponsor, and recruitment status when evaluating similar device driven investigations aimed at postpartum populations.

FAQ

1. 1. What devices are involved? EXOMIND BTL 699 2 and EMSELLA HPM 6000UF, each tested in active and sham modes.
2. 2. What conditions are being studied? Depressive symptoms and urinary incontinence in postpartum and early post childbirth women.
3. 3. Who funds the study? BTL Industries Ltd is listed as the sponsor.
4. 4. What is the status of the study? Recruitment is indicated as ongoing on the ClinicalTrials.gov record as of the provided time.
5. 5. Where can I find the official record? The ClinicalTrials.gov page for identifier NCT07413692 is linked in the article and can be accessed for the most current details.

Conclusion and implications for practice

This regulatory update highlights a four arm trial evaluating two noninvasive devices for postpartum depressive symptoms and urinary incontinence. The explicit inclusion of active and sham arms supports regulatory evaluation of device safety and potential efficacy signals while maintaining rigor in design. Stakeholders including clinicians, regulators, and device manufacturers should track the sponsor status and any protocol amendments to inform future regulatory submissions or post market surveillance considerations.

Disclaimer

This article provides informational content for professionals and is not legal or regulatory advice. Always refer to official registries and regulatory guidance for current requirements and interpretations.